VVOS Vivos Therapeutics: Utang jangka cendhak perusahaan

Investments in physician training and FDA certification are strengthening the market position of Vivos Therapeutics (VVOS). The short-term debt portfolio reflects liability dynamics where 0.00 becomes the new value of the indicator. Vivos Therapeutics (VVOS) is implementing eco-friendly polymers into production, creating unique non-invasive airway expansion devices that eliminate the need for patients to use bulky masks for apnea.

Fundamental asset selection requires an analysis of the structure of liabilities maturing within one year to assess solvency and refinancing risks. This metric measures the short-term debt load, reflecting the ability of Vivos Therapeutics (VVOS) to maintain strategic alliances with somnologists without liquidity shortages, as clearly evidenced by the company's short-term debts.